GB201709459D0 - Treatment for migraine - Google Patents

Treatment for migraine

Info

Publication number
GB201709459D0
GB201709459D0 GBGB1709459.0A GB201709459A GB201709459D0 GB 201709459 D0 GB201709459 D0 GB 201709459D0 GB 201709459 A GB201709459 A GB 201709459A GB 201709459 D0 GB201709459 D0 GB 201709459D0
Authority
GB
United Kingdom
Prior art keywords
migraine
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1709459.0A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intrabio Ltd
Original Assignee
Intrabio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59358204&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB201709459(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intrabio Ltd filed Critical Intrabio Ltd
Priority to GBGB1709459.0A priority Critical patent/GB201709459D0/en
Publication of GB201709459D0 publication Critical patent/GB201709459D0/en
Priority to PCT/IB2018/054676 priority patent/WO2018229738A1/en
Priority to MDE20200433T priority patent/MD3638370T2/ro
Priority to US16/622,785 priority patent/US11471434B2/en
Priority to LTEP18749124.6T priority patent/LT3638370T/lt
Priority to KR1020197038730A priority patent/KR102594130B1/ko
Priority to AU2018284330A priority patent/AU2018284330B2/en
Priority to CN201880039532.2A priority patent/CN111093772B/zh
Priority to BR112019026660-7A priority patent/BR112019026660B1/pt
Priority to PL18749124T priority patent/PL3638370T3/pl
Priority to ES18749124T priority patent/ES2847169T3/es
Priority to PT187491246T priority patent/PT3638370T/pt
Priority to JP2020519196A priority patent/JP7130739B2/ja
Priority to MA49396A priority patent/MA49396B1/fr
Priority to SI201830195T priority patent/SI3638370T1/sl
Priority to IL271211A priority patent/IL271211B2/en
Priority to SG11201912146RA priority patent/SG11201912146RA/en
Priority to SM20210037T priority patent/SMT202100037T1/it
Priority to EP18749124.6A priority patent/EP3638370B1/en
Priority to DK18749124.6T priority patent/DK3638370T3/da
Priority to RU2020100475A priority patent/RU2772278C2/ru
Priority to CA3067321A priority patent/CA3067321C/en
Priority to RS20210046A priority patent/RS61481B1/sr
Priority to MX2019014784A priority patent/MX387909B/es
Priority to HRP20210108TT priority patent/HRP20210108T1/hr
Priority to HUE18749124A priority patent/HUE053089T2/hu
Priority to ZA2019/08087A priority patent/ZA201908087B/en
Priority to CY20211100033T priority patent/CY1123860T1/el
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB1709459.0A 2017-06-14 2017-06-14 Treatment for migraine Ceased GB201709459D0 (en)

Priority Applications (28)

Application Number Priority Date Filing Date Title
GBGB1709459.0A GB201709459D0 (en) 2017-06-14 2017-06-14 Treatment for migraine
HRP20210108TT HRP20210108T1 (hr) 2017-06-14 2018-06-25 Liječenje migrene s acetil-leucinom
HUE18749124A HUE053089T2 (hu) 2017-06-14 2018-06-25 Migrén kezelése acetil-leucinnal
MA49396A MA49396B1 (fr) 2017-06-14 2018-06-25 Traitement de la migraine avec acétyl-leucine
SI201830195T SI3638370T1 (sl) 2017-06-14 2018-06-25 Tretiranje migrene z acetil-levcinom
US16/622,785 US11471434B2 (en) 2017-06-14 2018-06-25 Treatment for migraine
LTEP18749124.6T LT3638370T (lt) 2017-06-14 2018-06-25 Migrenos gydymas acetilleucinu
KR1020197038730A KR102594130B1 (ko) 2017-06-14 2018-06-25 편두통 치료
AU2018284330A AU2018284330B2 (en) 2017-06-14 2018-06-25 Treatment for migraine
CN201880039532.2A CN111093772B (zh) 2017-06-14 2018-06-25 偏头痛的治疗
BR112019026660-7A BR112019026660B1 (pt) 2017-06-14 2018-06-25 Uso de acetil-leucina ou seu sal para preparação demedicamento para tratar ou prevenir enxaqueca ou sintomas associados
PL18749124T PL3638370T3 (pl) 2017-06-14 2018-06-25 Leczenie migreny acetyloleucyną
ES18749124T ES2847169T3 (es) 2017-06-14 2018-06-25 Tratamiento de migraña con acetil-leucina
PT187491246T PT3638370T (pt) 2017-06-14 2018-06-25 Tratamento para hemicrania
JP2020519196A JP7130739B2 (ja) 2017-06-14 2018-06-25 片頭痛の治療
PCT/IB2018/054676 WO2018229738A1 (en) 2017-06-14 2018-06-25 Treatment for migraine
MDE20200433T MD3638370T2 (ro) 2017-06-14 2018-06-25 Tratamentul migrenei cu acetil-leucină
IL271211A IL271211B2 (en) 2017-06-14 2018-06-25 Acetyl-leucine for use in treatment of migraine
SG11201912146RA SG11201912146RA (en) 2017-06-14 2018-06-25 Treatment For Migraine
SM20210037T SMT202100037T1 (it) 2017-06-14 2018-06-25 Trattamento dell'emicrania con acetil-leucina
EP18749124.6A EP3638370B1 (en) 2017-06-14 2018-06-25 Treatment of migraine with acetyl-leucine
DK18749124.6T DK3638370T3 (da) 2017-06-14 2018-06-25 Behandling af migræne med acetyl-leucin
RU2020100475A RU2772278C2 (ru) 2017-06-14 2018-06-25 Лечение мигрени
CA3067321A CA3067321C (en) 2017-06-14 2018-06-25 Use of acetyle-leucine to prevent and/or treat migraine
RS20210046A RS61481B1 (sr) 2017-06-14 2018-06-25 Lečenje migrene acetil-leucinom
MX2019014784A MX387909B (es) 2017-06-14 2018-06-25 Tratamiento para la migra?a
ZA2019/08087A ZA201908087B (en) 2017-06-14 2019-12-05 Treatment for migraine
CY20211100033T CY1123860T1 (el) 2017-06-14 2021-01-18 Θεραπεια για την ημικρανια με ακετυλο-λευκινη

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1709459.0A GB201709459D0 (en) 2017-06-14 2017-06-14 Treatment for migraine

Publications (1)

Publication Number Publication Date
GB201709459D0 true GB201709459D0 (en) 2017-07-26

Family

ID=59358204

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1709459.0A Ceased GB201709459D0 (en) 2017-06-14 2017-06-14 Treatment for migraine

Country Status (25)

Country Link
US (1) US11471434B2 (https=)
EP (1) EP3638370B1 (https=)
JP (1) JP7130739B2 (https=)
KR (1) KR102594130B1 (https=)
CN (1) CN111093772B (https=)
AU (1) AU2018284330B2 (https=)
CY (1) CY1123860T1 (https=)
DK (1) DK3638370T3 (https=)
ES (1) ES2847169T3 (https=)
GB (1) GB201709459D0 (https=)
HR (1) HRP20210108T1 (https=)
HU (1) HUE053089T2 (https=)
IL (1) IL271211B2 (https=)
LT (1) LT3638370T (https=)
MA (1) MA49396B1 (https=)
MD (1) MD3638370T2 (https=)
MX (1) MX387909B (https=)
PL (1) PL3638370T3 (https=)
PT (1) PT3638370T (https=)
RS (1) RS61481B1 (https=)
SG (1) SG11201912146RA (https=)
SI (1) SI3638370T1 (https=)
SM (1) SMT202100037T1 (https=)
WO (1) WO2018229738A1 (https=)
ZA (1) ZA201908087B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111712239A (zh) * 2018-02-15 2020-09-25 内在生物技术有限公司 治疗不宁腿综合征的治疗剂

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3886986A1 (en) 2018-12-06 2021-10-06 IntraBio Ltd Deuterated analogs of acetyl-leucine

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8701662L (sv) * 1987-04-22 1988-10-23 Gelder Nico M Van Saett och medel foer att behandla neurologiska sjukdomar, exempelvis migraen genom paaverkan av nervcellerna
US20040127501A1 (en) * 2002-09-24 2004-07-01 Zhengming Chen Therapeutic agents useful for treating pain
US20060063827A1 (en) 2004-09-23 2006-03-23 Yu Ruey J Systemic administration of therapeutic amino acids and N-acetylamino acids
TWI287010B (en) * 2003-06-12 2007-09-21 Euro Celtique Sa Therapeutic agents useful for treating pain
SI1641775T1 (sl) * 2003-07-03 2009-08-31 Euro Celtique Sa 2-piridin alkinski derivati, uporabni za zdravljenje bolečine
DE602004017316D1 (de) * 2003-07-24 2008-12-04 Euro Celtique Sa Heteroaryl-tetrahydropyridylverbindungen, die sich für die behandlung bzw. die prävention von schmerzen eignen
SI1664016T1 (sl) * 2003-09-22 2009-04-30 Euro Celtique Sa Terapevtska sredstva, uporabna za zdravljenje bolečine
PL1664041T3 (pl) * 2003-09-22 2008-12-31 Euro Celtique Sa Przydatne do leczenia bólu związki fenylowo-karboksyamidowe
PL1727801T3 (pl) * 2003-12-30 2009-08-31 Euro Celtique Sa Piperazyny użyteczne do leczenia bólu
FR2905600B1 (fr) * 2006-09-13 2010-01-15 Pf Medicament Traitement des vertiges par l'acetyl-l-leucine.
TN2010000251A1 (fr) 2010-06-03 2011-11-11 Rekik Raouf N-acetyl-dl-leucine medicament neuro et retino protecteur
US8921373B2 (en) * 2010-06-22 2014-12-30 Shionogi & Co., Ltd. Compounds having TRPV1 antagonistic activity and uses thereof
LT2588130T (lt) 2010-06-25 2016-12-12 Shire Human Genetic Therapies, Inc. Terapinės priemonės pristatymas cns
MX340112B (es) * 2010-11-09 2016-06-27 Mannkind Corp Composicion que comprende un agonista de receptor de serotonina y una dicetopiperazina para el tratamiento de migrañas.
AU2012293417A1 (en) * 2011-08-10 2013-05-02 Purdue Pharma L.P. TRPV1 antagonists including dihydroxy substituent and uses thereof
ES2994242T3 (en) 2016-04-19 2025-02-05 Intrabio Ltd Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility
DK3359146T3 (en) 2016-08-11 2019-04-08 Intrabio Ltd PHARMACEUTICAL COMPOSITIONS AND USES AGAINST LYSOSOMAL STORAGE DISEASES
WO2018029658A1 (en) 2016-08-11 2018-02-15 Intrabio Limited Therapeutic agents for neurodegenerative diseases
HUE062729T2 (hu) 2017-03-28 2023-12-28 Intrabio Ltd Betahisztin, vagy gyógyászatilag elfogadható sója, és egy monoamin-oxidáz inhibitor, egy alanyban szédülés egy vagy több tünete kezelésében vagy megelõzésében történõ alkalmazásra
IL273929B2 (en) 2017-10-18 2024-11-01 Intrabio Ltd Therapeutic agents for neurodegenerative diseases
US12458614B2 (en) 2017-10-18 2025-11-04 Intrabio Ltd Therapeutic agents for improved mobility and cognitive function and for treating neurodegenerative diseases and lysosomal storage disorders
MA51836B1 (fr) 2018-02-15 2025-01-31 Intrabio Ltd Agents thérapeutiques permettant de traiter le syndrome des jambes sans repos
EP3886986A1 (en) 2018-12-06 2021-10-06 IntraBio Ltd Deuterated analogs of acetyl-leucine
SMT202400334T1 (it) 2019-03-02 2024-09-16 Intrabio Ltd (n-)acetil-l-leucina per il trattamento di lesioni cerebrali traumatiche
RS67283B1 (sr) 2019-06-28 2025-11-28 Intrabio Ltd Kombinovana terapija sa acetil-leucinom i miglustatom za lečenje bolesti lizozomskog skladištenja
WO2021144720A1 (en) 2020-01-13 2021-07-22 Intrabio Ltd Treatment of late-onset neurodegenerative diseases in heterozygous npc1 gene mutation carriers

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111712239A (zh) * 2018-02-15 2020-09-25 内在生物技术有限公司 治疗不宁腿综合征的治疗剂

Also Published As

Publication number Publication date
MA49396B1 (fr) 2021-03-31
DK3638370T3 (da) 2021-01-25
MA49396A (fr) 2020-04-22
KR20210013518A (ko) 2021-02-04
RU2020100475A3 (https=) 2021-10-22
CN111093772A (zh) 2020-05-01
HRP20210108T1 (hr) 2021-03-19
SI3638370T1 (sl) 2021-04-30
SMT202100037T1 (it) 2021-03-15
BR112019026660A2 (pt) 2020-07-14
ZA201908087B (en) 2024-11-27
AU2018284330B2 (en) 2024-03-14
IL271211A (en) 2020-01-30
US20200253905A1 (en) 2020-08-13
PT3638370T (pt) 2021-01-26
HUE053089T2 (hu) 2021-06-28
MD3638370T2 (ro) 2021-04-30
MX2019014784A (es) 2021-11-16
JP2020526575A (ja) 2020-08-31
SG11201912146RA (en) 2020-01-30
IL271211B2 (en) 2024-01-01
AU2018284330A1 (en) 2020-01-02
KR102594130B1 (ko) 2023-10-24
EP3638370A1 (en) 2020-04-22
JP7130739B2 (ja) 2022-09-05
LT3638370T (lt) 2021-03-25
EP3638370B1 (en) 2020-11-11
CY1123860T1 (el) 2022-05-27
ES2847169T3 (es) 2021-08-02
PL3638370T3 (pl) 2021-05-17
IL271211B1 (en) 2023-09-01
RS61481B1 (sr) 2021-03-31
CN111093772B (zh) 2023-11-03
CA3067321A1 (en) 2018-12-20
MX387909B (es) 2025-03-19
RU2020100475A (ru) 2021-07-14
WO2018229738A1 (en) 2018-12-20
US11471434B2 (en) 2022-10-18

Similar Documents

Publication Publication Date Title
IL291153A (en) Methods for treating or preventing migraine headaches
IL265343A (en) Treatment of persistent migraine
GB201608885D0 (en) Treatment
GB2567616B (en) Treatment method
GB201811679D0 (en) Treatment apparatus
GB2571601B (en) Treatment method
SG11202001806TA (en) Treatment method
SG10201913372QA (en) Treatment apparatus
IL271211A (en) Migraine treatment
PT3250218T (pt) Péptido natkide para o tratamento da obesidade
GB201718985D0 (en) Treatment
ZA201805215B (en) Preparation for nasal-nasopharyngeal treatment
GB201713650D0 (en) Treatment
GB201706955D0 (en) Treatment
GB201711677D0 (en) Combination treatment
GB201704949D0 (en) Combination treatment
GB201617107D0 (en) Treatment
GB201612260D0 (en) Treatment
GB201612193D0 (en) Treatment
GB201609683D0 (en) Treatment
GB201617380D0 (en) Treatment for Osteoarthritis

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)